Product logins

Find logins to all Clarivate products below.


Acute Myeloid Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)

Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has long been the mainstay of AML treatment, the recent approval of new drugs, such as Revuforj (revumenib) and Vanflyta (a second-generation FLT-3 inhibitor), indicates a trend toward more-targeted therapies. Moreover, both early- and late-phase pipelines for AML include various drug classes such as menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. Despite the recent failures of several drugs in late-phase development, we expect the expansion of existing therapies into additional patient populations and the approval of new treatments to lead to notable growth in the AML drug therapy market.

Questions answered:

  • How large are the clinically and commercially relevant drug-treatable AML populations, and how will drug-treatable rates change (if at all) over the 2024-2034 forecast period?
  • What is the current treatment landscape for AML? What are the key takeaways from expert interviews?
  • What are the most promising therapies in the pipeline, and how will they influence the AML therapy market in the future?
  • What are the primary factors driving and limiting the AML market, and how will this market evolve over the forecast period?

Geographies: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading hematologist-oncologists. Survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed incidence of AML by country, clinically and market relevant drug-treatable populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key AML therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and late-phase emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

  • Optimize your long-term disease and development strategy.
  • Quantify market potential for your pipeline assets and those of your competitors.
  • Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
  • Gauge the commercial outlook and impact of key market events.

Table of contents


Related Market Assessment Reports

Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Bipolar Disorder – Current Treatment – Current Treatment: Physician Insights – Bipolar Disorder (EU5)
Bipolar disorder (BD) is a spectrum disorder characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Lithium…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…